Nivolumab Feasible for Early Stage Resectable NSCLC
Study findings suggest that anti-PD1 immunotherapy may have significant activity among patients with early stage NSCLC.
ESMO 2016
Abiraterone Lacks Activity in Recurrent High Grade Serous Epithelial Ovarian Cancer
Further investigation is warranted to assess the activity of abiraterone among patients with low grade serous EOC.
Alisertib May Benefit Some Patients With Neuroendocrine Prostate Cancer
Aurora kinase A inhibition with alisertib monotherapy may benefit a subset of patients with neuroendocrine prostate cancer (NEPC).
Abemaciclib Associated With a Greater Reduction in Ki67 Than Anastrozole in Breast Cancer
Among women with HER2-negative breast cancer, treatment with abemaciclib reduced Ki67 levels more than anastrozole.
Ceritinib Active in ALK Inhibitor-naive Patients With ALK+ NSCLC
Ceritinib induced robust whole body responses in anaplastic lymphoma kinase (ALK) inhibitor-naive patients with ALK-rearranged non-small cell lung cancer (NSCLC).
Vandetanib Active in RET-rearranged Advanced NSCLC
Vandetanib demonstrates antitumor activity among patients with advanced RET-rearranged non-small cell lung cancer (NSCLC).
Nivolumab May Be Better Than BSC for Advanced Hepatocellular Carcinoma
Second-line treatment with nivolumab was well tolerated and associated with encouraging preliminary activity among patients with hepatocellular carcinoma.
Everolimus + Letrozole Efficacious in ER+, HER2- Advanced Breast Cancer
Everolimus plus letrozole is efficacious as a first-line treatment regimen for patients with estrogen receptor (ER)-positive, HER2-negative advanced breast cancer.
Trabectedin Improves PFS vs Best Supportive Care in Sarcoma
Compared with best supportive care, trabectedin significantly improves progression-free survival among patients with pretreated advanced soft tissue sarcoma.
Adding Evofosfamide to Doxorubicin Fails to Improve OS in Sarcoma
Among patients with advanced soft tissue sarcoma, adding evofosfamide to doxorubicin failed to improve overall survival compared with doxorubicin alone.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Next post in ESMO 2016
Loading... 
Loading...